Abstract
Prostate gland represents an auxiliary male gonadal gland. The hormone-induced growth of prostate gland is responsible for characteristic disturbances in urination at advanced age.
Clinically, we term it LUTS/BHP or symptoms of lower urinary tract based on benign prostate hyperplasia. Incidence and prevalence of this disease increase with age.
Therapy is preferentially aimed at the maintenance of the quality of life of patients with choice of monitoring, use of pharmacologically active compounds or surgical intervention. Pharmacotherapy of benign prostate hyperplasia uses phytopharmaceuticals, alphablockers and 5-alpha reductase blockers.
Pharmaceutical care finds its use during diagnostics of this disease, in particular while providing an analysis of patient's problems, consultation concerning symptomatic treatment and a complete information service during dispensation.